ClinicalTrials.gg
CompletedNCT06596876Updated Nov 16, 2026

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

A Phase 3 interventional study of HRG2010; Sustained-release Carbidopa/Levodopa administered placebo and Sustained-release Carbidopa/Levodopa; HRG2010 placebo in Parkinson's Disease, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
33rd of 211
165 · median 47
Started
2024
with 30 others
Phase 3
18 of 279
2 open now
Registered
186th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 33rd largest by enrollment of the 211 interventional ones that give a count, is one of 31 that started in 2024, is one of 18 in phase 3, and was the 186th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female who are at age 40\~80 years with PD, consistent with the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria and who are being treated with stable regimens of DDCI+LD but experiencing motor fluctuations.
  2. (MMSE) ≥ 24 at Screening Visit.
  3. Hoehn and Yahr Stage I-IV when "on" at Screening Visit.
  4. At Screening, the participant has predictable "Off" periods.
  5. Able and willing to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with atypical or secondary parkinsonism.
  2. History of narrow angle glaucoma、peptic ulcer disease or upper gastrointestinal hemorrhage.
  3. Had prior functional neurosurgical treatment for PD or if such procedure(s) are planned or anticipated during the study period.
  4. Nonresponsive to LD therapy.
  5. In the opinion of the clinical investigator, Subjects who should not participate in the study.
  6. Subjects who are allergic to the drug to be used in this study.
  7. Pregnant or breastfeeding.
  8. Participants who have previously participated in an HRG2010 study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo

    Drug: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo

  • Active comparator
    Sustained-release Carbidopa/Levodopa and HRG2010 placebo

    Drug: Sustained-release Carbidopa/Levodopa; HRG2010 placebo

Interventions

  • DrugHRG2010; Sustained-release Carbidopa/Levodopa administered placebo

    Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.

  • DrugSustained-release Carbidopa/Levodopa; HRG2010 placebo

    Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.

06

What researchers measure

Primary outcomes

  1. Change from baseline in "Off" time at Week 21

    Time frame: Last three days collected at the end of treatment period, at Week 21

Secondary outcomes

  1. Change from baseline in "On" Time Without Troublesome Dyskinesia at Week 21

    Time frame: Last three days collected at the end of treatment period, at Week 21

  2. Change from baseline in the Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at Week 21

    Time frame: Week 21

  3. Change from baseline in the 39-item Parkinson's Disease Questionnaire (PDQ-39) at Week 21

    Time frame: Week 21

  4. Adverse events

    Time frame: Week 23

07

Study locations

1 site
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jan 2026, 14 months.

Of 40 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 14 months is below that.

Counting every sponsor, half of 68 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2025 → Jan 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Sep 19, 2024
StartActual
Nov 6, 2024
Primary completionActual
Jan 29, 2026was Oct 2025
CompletionActual
Jan 29, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 9, 2025→Jan 29, 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Oct 9, 2025→Jan 29, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06596876
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 6, 2024
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion